Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab

Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab

Abstract Background Metastatic TNBC (mTNBC) has a poor prognosis and few treatment options. The anti-PD-L1 antibody atezolizumab demonstrated clinical activity in mTNBC patients with PD-L1-positive tumor-infiltrating immune cells. The current study describes the tumor immune microenvironment (TiME)...

Full description

Bibliographic Details
Main Authors: Luciana Molinero, Yijin Li, Ching-Wei Chang, Sophia Maund, Maureen Berg, Jeanne Harrison, Marcella Fassò, Carol O’Hear, Priti Hegde, Leisha A. Emens
Format: Article
Language:English
Published: BMJ Publishing Group 2019-10-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Triple negative breast cancer (TNBC)
Atezolizumab
PD-L1
Online Access:http://link.springer.com/article/10.1186/s40425-019-0740-8

Internet

http://link.springer.com/article/10.1186/s40425-019-0740-8

Similar Items